MSCs as Medical Stockpiled Countermeasures: Cellular “First Responders” for COVID-19 and Future Emerging Biothreats

Authored by Tim Olsen, PhD, RoosterBio Inc.

Where are we now in our therapeutic response to COVID?

As of writing this article, over 1.5 Million Americans have confirmed cases of COVID-19 and 90,000 lives have been lost. [1] This global biothreat has not only claimed lives and infected patients to cause comorbid diseases like acute respiratory distress syndrome (ARDS) that overwhelm the hospital infrastructure, [2] [3] [4] but it’s also crippled the U.S. economy and set record numbers for unemployment or permanent ex-employment. [5] More than ever, America requires a rapid response to fight the spread of the virus and treat those infected.

In an attempt to re-allocate existing drugs for off-label use, early studies with hydroxychloroquine and remdesivir have not yet conclusively demonstrated objective benefit for COVID patients as monotherapies. [6] [7] [8] Nevertheless, times of crisis can fuel interdisciplinary efforts toward rapid innovation.  Over the past few months, we observed new public-private partnerships to rapidly develop, test, and deploy a variety of Medical Countermeasures (MCM) for use on the front lines by health care professionals to combat COVID. [9] [10] [11] [12] [13] One promising technology are human mesenchymal stromal/stem cells (hMSCs). With an excellent safety profile established over hundreds of clinical trials and tens of thousands of patients dosed, MSCs are actively being used in the clinic for indications including acute respiratory distress syndrome (ARDS), acute lung injury, pneumonia, and more. [14]

Promising preliminary results are already reported from the first studies in COVID patients. [15] [16] [17] [18] [19] Not only are MSCs being used experimentally to treat patients now, but advances in scalable manufacturing could enable the plausible option for these cellular products to be produced at an emergency response level to store in the Strategic National Stockpile (SNS), [20] for off-the-shelf use in future public health emergencies related to chemical, biological, radiological or nuclear (CBRN) threats. [21] [22] [23] [24] [25] [26] [27]  Incidentally, BARDA recently re-opened a grant opportunity communicated via BAA-18-100-SOL-00003, updated on 24-April-2020, with application window to close on 31-Oct-2020 (formerly 31-Oct-2019).

This Broad Agency Announcement (BAA; latest Amendment here)

“…is to solicit proposals that focus on one or more of the following areas of interest as listed here and further described in Part I.

Research and Development Areas of Interest:

  1. CBRN Vaccines
  2. Antitoxins and Therapeutic Proteins
  3. Antibacterials
  4. Radiological/Nuclear Threat Medical Countermeasures
  5. Chemical Threat Medical Countermeasures
  6. Burn Medical Countermeasures
  7. Diagnostics
  8. Influenza and Emerging Infectious Diseases (IEID) Vaccines
  9. Influenza and Emerging Infectious Diseases (IEID) Therapeutics
  10. Respiratory Protective Devices
  11. Ventilators
  12. MCM Production Platform Systems
  13. Modeling as an Enabling Technology for Influenza, Emerging Infectious Disease, and CBRN Threat
  14. Visual Analytics an Enabling Technology for Influenza, Emerging Infectious Disease, and CBRN Threats”

Although these proposal “areas of interest” in the latest BAA must now necessarily be COVID-19 focused, it’s obvious how one might employ MSCs as stockpiled countermeasures—or as therapies directed at Influenza and Emerging and Infectious Diseases (IEIDs). While Countermeasures Areas of Interest need to be at least at a Technology Readiness Level (TRL)[28] of 4 or more (“Candidate Optimization and Non-GLP In Vivo Demonstration of Activity and Efficacy”), IEID therapeutics need to be at TRL-6 (“as evidenced by release of a final report for a Phase 1 clinical study and a US IND, unless otherwise indicated”).  To see if a cellular therapeutic or countermeasure product or process fits with BAA-18-100-SOL-00003, [29] or a different funding vehicle, you can request to schedule a “CoronaWatch” advisory meeting with the Federal Government HERE. [30]

How does the United States respond to public health emergencies like COVID?

The U.S. Department of Health and Human Services began discussions of a readily deployable supply of emergency medical countermeasures in 1999. The first real deployments were during the aftermath of the September 11th attacks and the anthrax threat in 2001. A critical attribute of the mobilization of these emergency supplies is their at-scale manufacture and pre-packaging, such that these ‘push packages’ could be deployed anywhere in the United States with 12 hours’ notice. In 2002, The Strategic National Stockpile (SNS) [31] was officially created and codified in the Public Health Service Act to be a supplement to state and local supplies during public health emergencies.

Although full details are classified, examples of the SNS inventory include ventilators, antibiotics, antitoxins, personal protective equipment, vaccines and more. As new threats emerge, new technologies are called upon to be deployed to help combat the threat. However, oftentimes these technologies are not at commercial level manufacturing, and a gap exists to accelerate small scale manufacturing to pandemic level manufacturing; access to these innovative solutions is thus restricted during times of need. This conundrum gave rise to the U.S. Department of Health and Human Services directive to establish the Biomedical Advanced Research and Development Authority (BARDA) to protect America from CBRN threats, as well as from pandemic influenza and emerging infectious diseases. BARDA focuses on medical countermeasure development and deployment of diagnostics (biothreat detection), vaccines (biothreat prevention), and therapeutics (biothreat mitigation). By providing funding and resources, BARDA helps to bridge the gap between early stages of development and full-scale manufacturing for acquisition of approved medical countermeasures for the Strategic National Stockpile. Thus far, BARDA supported 42 FDA approvals for products for threats against National Security.

The largest deployment of MCMs from the SNS, [32] with support from BARDA, was for the H1N1 influenza in 2009, where 12.5M antiviral regimens, 19.6M pieces of PPE, 85.1M N95 respirators, and 2,129 regimens of Peramivir IV were distributed across the country.

Sound familiar?

Currently, the SNS has $7B of inventory. [33] The COVID supply [34] deployment, and procurement from countries around the world, promises to trump any national health emergency to date when it is all said and done as the country returns to a ‘new normal.’

Learning from COVID to prepare for the ‘next one.’

As dismal as the death toll has been for COVID-19 thus far, experts warn that the next global health emergency crisis could be even worse, and is a matter of not ‘if,’ but ‘when.’ The reality is that there are still unknowns regarding SARS-CoV-2’s persistence, its infectivity, the immunity of inoculated humans, its amenability to antiviral drug cocktails, and its sequelae of long-term damages to recovering patients. For example, mildly sick COVID patients younger than 50 [35] are beginning to appear in hospitals, presenting with stroke at unprecedented rates. [36] [37] COVID-19’s effects on other vital, non-lung related organs and physiology may be non-trivial for many.[38] [39] [40] [41] [42] Therefore, generalized regenerative medicine technology approaches, which aren’t pathogen, indication, or disaster specific, could be ideal candidates to be added into the National Stockpile.

In early trials with hMSCs aimed at COVID-19 indications, clinical data are consistent with what may be interpreted as the first signs of safety and efficacy, pending future validation with more higher powered studies. [43] [44] Mesoblast and Pluristem have reported 83% (n=12) [45] and 100% (n=7) [46] survival rates, respectively, from their initial compassionate use studies for COVID patients experiencing acute respiratory complications. [47] While promising, larger studies will be required to demonstrate concomitant safety and efficacy, and multiple groups are moving quickly to do just that. Athersys has received FDA approval for initiating a pivotal Phase 2/3 clinical study of its stem cell therapy, Multistem, on 400 patients with COVID induced ARDS. [18] The World Health Organization has reported that ARDS is the leading cause of death in COVID infected patients, highlighting the impact of Athersys’ study. [48] BARDA has designated Athersys’ Cell Therapy as ‘Highly Relevant’ for COVID-19, representing another opportunity for private-public partnership.

MSCs have not only been shown to be compelling for early studies related to COVID indications, but have also been reported via preclinical data to be effective in treating a variety of model CBRN threats. [20] [21] [49] As of May, 2020, ClinicalTrials.gov has at least 16 trials listed for burns (chemical and trauma induced), 129 trials listed for infection, and 25 trials listed for inflammation and systemic inflammatory response syndrome. [50] Another intriguing characteristic of MSCs is their ability to be modified via genetic engineering or genome editing, setting the stage to create a “plug-and-play” MSC platform with cross-functionality to combat many emerging threats. [51] [52] [53] [54] [55] [56] [57]

When manufacturing materials for a stockpile, the transportation logistics, cold chain, and shelf-life are critical. [58] [59] [60] [61] [62] [63] MSCs have been shown to be successfully banked for years under proper cryopreservation conditions. MSC-derived extracellular vesicles (MSC-EVs) have commanded significant interest over the years as a potential treatment for ARDS due to similar functionality with their parent MSCs and eased storage logistics, [26] [64] [65] [66] since freeze drying via lyophilization can greatly extend shelf- life. [67] Human clinical trials are now underway involving use of MSC-EVs against severe COVID-19, [68] and one preliminary result from a small study via NYU’s Grossman School of Medicine [69] is consistent with preclinical data [70] that could suggest signs of benefit.  Nevertheless, it is strongly advised that studies with EVs adhere to stringent standards of consistency and quality, made via material generated under current Good Manufacturing Practices (cGMP), weighing potential risks and benefits, and minimizing hazard. [68] RoosterBio’s most recent blogs discuss the imperative of safety pertaining to MSCs in the COVID-19 crisis, [71] and the complex manufacturing considerations of large scale MSC-EV dose preparation for trials directed at the pandemic’s victims. [72]

Rather than having to wait for months or years for trials to be initiated and completed during national health emergencies, having a readily available supply of cryopreserved MSCs and MSC-EVs to be deployed via the SNS 12-hour Push Packs can aid in front line countermeasures for patients in need.  The duration from culture seeding to harvest and dose-filling of hMSCs or other regenerative cell types can last from days (under the most state of the art bioprocesses) [24] [73] to weeks or months.  Ability to rapid deploy a life-saving therapeutic at the “point of panic” may be critical when dealing with acute illnesses or injuries in national emergencies.

It took a pandemic to provide the fuel for scaling cell manufacturing to new heights.

Manufacturing at scales required to fulfill the needs during a pandemic is no small feat. MSCs were once written off as a viable technology because it was thought that they could not be scaled to large stirred tank bioreactor systems to meet commercially or clinically relevant lot sizes, or in this case a global pandemic response. Over the last decade, tremendous progress has been made in the scalable manufacturing of MSCs. [24] [25] [26] [27] [73] Several groups have achieved manufacturing runs at the 50L scale and above. [74] [75] Prior to pandemic, the demand for manufacturing programs was to create batch sizes to fuel early to mid-stage clinical trials with up to a few hundred patients. Unoptimized 2D-flask based systems have been deployed for these early trials, but the industry consensus is that scalable stirred tank bioreactor systems are the future. Thus, there was no demand to scale to 500L or 2,000L systems that could produce thousands of MSC doses at a time. Not because it wasn’t feasible before in development labs, but the input costs alone (cells, media, reagents, consumables, labor) are north of $1M per run. Public-private collaborations and the associated funding will be absolutely critical to obtain the resources required to develop the infrastructure for manufacturing MSCs for the SNS.

The greater our complacency, the greater the crisis will be.

Urgency is key to deployment of patient ready therapeutics. Experts of emerging diseases have indicated that it is not a matter of ‘if’ the next pandemic comes, but rather ‘when.’ Some models estimate that up to a large fraction of the USA could be exposed or infected by COVID-19. [76] The current mortality rate of COVID-19 can be approximated by the number of deaths divided by the number of clinical cases (subclinical cases excluded). It is about 6% in the USA and 7% globally. [77] But what if the next global threat rivals the 50% mortality rate of Ebola? [78] A well prepared and disciplined defense is the worst enemy of any emerging health threat. Given their versatility and manufacturability, MSCs would be a valuable therapeutic asset as a broad-spectrum front-line defense for addition to the SNS as a MCM against the unknown, but certainly developing, emerging public health threats of the future.

 

References
  1. Dong, E., Du, H., and Gardner, L., An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect Dis, 2020. 10.1016/S1473-3099(20)30120-1
  2. Specht, L. What does the coronavirus mean for the U.S. health care system? Some simple math offers alarming answers. STATnews.com 2020; Available from: https://www.statnews.com/2020/03/10/simple-math-alarming-answers-covid-19/.
  3. Ventilator Stockpiling and Availability in the US. Johns Hopkins Center for Health Security, centerforhealthsecurity.org 2020; Available from: http://www.centerforhealthsecurity.org/resources/COVID-19/200214-VentilatorAvailability-factsheet.pdf.
  4. Wang, C., et al., A novel coronavirus outbreak of global health concern. Lancet, 2020. 395(10223): p. 470-473. 10.1016/S0140-6736(20)30185-9
  5. Coibion, Olivier, Gorodnichenko, Yuriy, and Weber, Michael, Labor Markets During the COVID-19 Crisis: A Preliminary View. 2020, National Bureau of Economic Research.
  6. Grein, Jonathan, et al., Compassionate Use of Remdesivir for Patients with Severe Covid-19. New England Journal of Medicine, 2020. 10.1056/NEJMoa2007016
  7. Li, G. and De Clercq, E., Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nat Rev Drug Discov, 2020. 19(3): p. 149-150. 10.1038/d41573-020-00016-0
  8. Kupferschmidt, K. and Cohen, J., Race to find COVID-19 treatments accelerates. Science, 2020. 367(6485): p. 1412-1413. 10.1126/science.367.6485.1412
  9. Prompetchara, E., Ketloy, C., and Palaga, T., Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic. Asian Pac J Allergy Immunol, 2020. 38(1): p. 1-9. 10.12932/AP-200220-0772
  10. Abbott, Timothy R., et al., Development of CRISPR as a prophylactic strategy to combat novel coronavirus and influenza. bioRxiv, 2020: p. 2020.03.13.991307. 10.1101/2020.03.13.991307
  11. Kilianski, A., et al., Pathosphere.org: pathogen detection and characterization through a web-based, open source informatics platform. BMC Bioinformatics, 2015. 16: p. 416. 10.1186/s12859-015-0840-5
  12. Chen, Wen-Hsiang, et al., The SARS-CoV-2 Vaccine Pipeline: an Overview. Current Tropical Medicine Reports, 2020: p. 1-4.
  13. Amanat, F. and Krammer, F., SARS-CoV-2 Vaccines: Status Report. Immunity, 2020. 10.1016/j.immuni.2020.03.007
  14. Cell Trials Data. CellTrials.org 2020; Available from: https://celltrials.org/about.
  15. Zikuan Leng, Rongjia Zhu, Wei Hou, Yingmei Feng, Yanlei Yang, Qin Han, Guangliang Shan, Fanyan Meng, Dongshu Du, Shihua Wang, Junfen Fan, Wenjing Wang, Luchan Deng, Hongbo Shi, Hongjun Li, Zhongjie Hu, Fengchun Zhang, Jinming Gao, Hongjian Liu, Xiaoxia Li, Yangyang Zhao, Kan Yin, Xijing He, Zhengchao Gao, Yibin Wang, Bo Yang, Ronghua Jin, Ilia Stambler, Lee Wei Lim, Huanxing Su, Alexey Moskalev, Antonio Cano, Sasanka Chakrabarti, Kyung-Jin Min, Georgina Ellison-Hughes, Calogero Caruso, Kunlin Jin, Robert Chunhua Zhao, Transplantation of ACE2- Mesenchymal Stem Cells Improves the Outcome of Patients with COVID-19 Pneumonia. Aging and disease: p. 216-228. 10.14336/ad.2020.0228
  16. Williams, Ruth. Are Mesenchymal Stem Cells a Promising Treatment for COVID-19? The Scientist 2020; Available from: https://www.the-scientist.com/news-opinion/are-mesenchymal-stem-cells-a-promising-treatment-for-covid-19–67402
  17. Hildreth, Cade. Mesoblast To Evaluate Anti-Inflammatory Cell Therapy Remestemcel-L For Treatment Of COVID-19 Lung Disease. Bioinformant 2020; Available from: https://bioinformant.com/mesoblast-remestemcel-l-covid-19/.
  18. Hildreth, Cade. Athersys Milestones Related to ARDS. BioInformant 2020; Available from: https://bioinformant.com/athersys-barda-covid-19/.
  19. Hildreth, Cade. Pluristem Treated First Three COVID-19 Patients in Israel under Compassionate Use. BioInformant 2020; Available from: https://bioinformant.com/pluristem-covid19-treatment/.
  20. Eaton, E. B., Jr. and Varney, T. R., Mesenchymal stem cell therapy for acute radiation syndrome: innovative medical approaches in military medicine. Mil Med Res, 2015. 2: p. 2. 10.1186/s40779-014-0027-9
  21. Angelini, D. J., et al., Chemical warfare agent and biological toxin-induced pulmonary toxicity: could stem cells provide potential therapies? Inhal Toxicol, 2013. 25(1): p. 37-62. 10.3109/08958378.2012.750406
  22. Rowley, Jon, et al., Meeting lot-size challenges of manufacturing adherent cells for therapy. BioProcess Int, 2012. 10(3): p. 7.
  23. Christy, Barbara A, et al. Mesenchymal Stem Cells Grown in a Bioreactor Are Functionally Similar to Those Grown in Monolayer Culture. in 2019 Annual Meeting. 2019. AABB.
  24. Kirian, RD, et al., SCALING A XENO-FREE FED-BATCH MICROCARRIER SUSPENSION BIOREACTOR SYSTEM FROM DEVELOPMENT TO PRODUCTION SCALE FOR MANUFACTURING XF hMSCs. Cytotherapy, 2019. 21(5): p. S71-S72.
  25. Takacs, Joseph, Adlerz, Katrina. hUC-MSC Exhibit Robust Proliferation in 3D Bioreactor System. RoosterBio Blog 2020; Available from: https://www.roosterbio.com/cell-therapy/huc-msc-exhibit-robust-proliferation-in-3d-bioreactor-system/.
  26. Adlerz, Katrina. Generating MSC-EVs With a Scalable Manufacturing System. RoosterBio Blog 2019; Available from: https://www.roosterbio.com/evs-exosomes/generating-msc-evs-with-a-scalable-manufacturing-system/.
  27. Carson, J., Farrance, I., Getz, J., and Jon A. Rowley. Scalable MSC Manufacturing Matters in a Rapid Response to COVID-19. RoosterBio Blog 2020; Available from: https://www.roosterbio.com/biomanufacturing/scalable-msc-manufacturing-matters-in-a-rapid-response-to-covid-19/.
  28. MedicalCountermeasures.gov. INTEGRATED TRLS for Medical Countermeasure Products (Drugs and Biologics). 2004; Available from: https://www.medicalcountermeasures.gov/trl/integrated-trls/.
  29. Services, United States Department of Health and Human. Biomedical Advanced Research and Development Authority (BARDA) Broad Agency Announcement (BAA). 2020; Available from: https://beta.sam.gov/opp/0bba3967c3404799aba43a1a9b3456ed/view.
  30. MedicalCountermeasures.gov. REQUEST A USG CORONAWATCH MEETING. 2020; Available from: https://www.medicalcountermeasures.gov/Request-BARDA-TechWatch-Meeting/.
  31. Preparedness, Bioterrorism, Public health security and bioterrorism preparedness and response act of 2002. Public law, 2002. 107(188): p. 188.
  32. National Academies of Sciences, Engineering and Medicine. The Strategic National Stockpile: Origin, Policy Foundations, and Federal Context. in The Nation’s Medical Countermeasure Stockpile: Opportunities to Improve the Efficiency, Effectiveness, and Sustainability of the CDC Strategic National Stockpile: Worksh
  33. Williams, Greg Burel and Denise. The Evolution of the Strategic National Stockpile. ASPR Blog 2019; Available from: https://www.phe.gov/ASPRBlog/Pages/BlogArticlePage.aspx?PostID=356.
  34. SCHLANGER, ZOË. Begging for Thermometers, Body Bags, and Gowns: U.S. Health Care Workers Are Dangerously Ill-Equipped to Fight COVID-19. time.com 2020; Available from: https://time.com/5823983/coronavirus-ppe-shortage/.
  35. Grens, Kerry. Strokes Reported Among Some Middle-Aged COVID-19 Patients. TheScientist 2020; Available from: https://www.the-scientist.com/news-opinion/strokes-reported-among-some-middle-aged-covid-19-patients-67482.
  36. Helms, J., et al., Neurologic Features in Severe SARS-CoV-2 Infection. N Engl J Med, 2020. 10.1056/NEJMc2008597
  37. Cha, Ariana Eunjung. Young and middle-aged people, barely sick with covid-19, are dying of strokes. 2020; Available from: https://www.washingtonpost.com/health/2020/04/24/strokes-coronavirus-young-patients/.
  38. Lippi, A., et al., SARS-CoV-2: At the Crossroad Between Aging and Neurodegeneration. Mov Disord, 2020. 10.1002/mds.28084
  39. Clerkin, K. J., et al., Coronavirus Disease 2019 (COVID-19) and Cardiovascular Disease. Circulation, 2020. 10.1161/CIRCULATIONAHA.120.046941
  40. Pan, X. W., et al., Identification of a potential mechanism of acute kidney injury during the COVID-19 outbreak: a study based on single-cell transcriptome analysis. Intensive Care Med, 2020. 10.1007/s00134-020-06026-1
  41. Liang, W., et al., Diarrhoea may be underestimated: a missing link in 2019 novel coronavirus. Gut, 2020. 10.1136/gutjnl-2020-320832
  42. Cao, X., COVID-19: immunopathology and its implications for therapy. Nat Rev Immunol, 2020. 10.1038/s41577-020-0308-3
  43. Lim, Mayasari. Can MSCs Treat Patients with COVID-19? 2020; Available from: https://www.roosterbio.com/covid-19/can-stem-cells-treat-patients-with-covid-19/.
  44. Smith, James Andrew, et al., Proliferation of mesenchymal stem cell trials for COVID-19: risks and recommendations. 2020.
  45. Terry, Mark. Mesoblast’s Stem Cell Therapy Shows 83% Survival in Ventilator-Dependent COVID-19 Patients. biospace.com 2020; Available from: https://www.biospace.com/article/mesoblast-ltd-s-stem-cell-therapy-shows-83-percent-survival-in-covid-19-patients/.
  46. Keown, Alex. Preliminary Data from Pluristem’s PLC Cell Program Shows Promise in COVID-19. biospace.com 2020; Available from: https://www.biospace.com/article/preliminary-data-from-pluristem-s-plc-cell-program-is-promising-in-covid-19/.
  47. Lim, Mayasari. The Race to Beat COVID-19 with hMSCs Revs Up. RoosterBio Blog 2020; Available from: https://www.roosterbio.com/covid-19/the-race-to-beat-covid-19-with-hmscs-revs-up/.
  48. Organization, World Health, Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19). 2020.
  49. Herdrich, B. J., Lind, R. C., and Liechty, K. W., Multipotent adult progenitor cells: their role in wound healing and the treatment of dermal wounds. Cytotherapy, 2008. 10(6): p. 543-50. 10.1080/14653240802345820
  50. ClinicalTrials.gov. QUERY- 1175 Studies found for: mesenchymal stem cell OR mesenchymal stromal cell. 2020; Available from: https://clinicaltrials.gov/ct2/results/browse?term=mesenchymal+stem+cell+OR+mesenchymal+stromal+cell&brwse=cond_alpha_all.
  51. Fei, S., et al., The antitumor effect of mesenchymal stem cells transduced with a lentiviral vector expressing cytosine deaminase in a rat glioma model. J Cancer Res Clin Oncol, 2012. 138(2): p. 347-57. 10.1007/s00432-011-1104-z
  52. Cho, H. M., et al., Targeted Genome Engineering to Control VEGF Expression in Human Umbilical Cord Blood-Derived Mesenchymal Stem Cells: Potential Implications for the Treatment of Myocardial Infarction. Stem Cells Transl Med, 2017. 6(3): p. 1040-1051. 10.1002/sctm.16-0114
  53. Cheung, W. Y., et al., Efficient Nonviral Transfection of Human Bone Marrow Mesenchymal Stromal Cells Shown Using Placental Growth Factor Overexpression. Stem Cells Int, 2018. 2018: p. 1310904. 10.1155/2018/1310904
  54. Kojima, R., Scheller, L., and Fussenegger, M., Nonimmune cells equipped with T-cell-receptor-like signaling for cancer cell ablation. Nat Chem Biol, 2018. 14(1): p. 42-49. 10.1038/nchembio.2498
  55. Meng, X., et al., Transplantation of CRISPRa system engineered IL10-overexpressing bone marrow-derived mesenchymal stem cells for the treatment of myocardial infarction in diabetic mice. J Biol Eng, 2019. 13: p. 49. 10.1186/s13036-019-0163-6
  56. Han, J., et al., Genetically modified mesenchymal stem cell therapy for acute respiratory distress syndrome. Stem Cell Res Ther, 2019. 10(1): p. 386. 10.1186/s13287-019-1518-0
  57. Alba Gonzalez-Junca, Archana Nagaraja, Alyssa Mullenix, Russell M Gordley, Daniel O Frimannsson, Anissa Benabbas, Chen-Ting Lee, Tiffany A Truong, Allison Quach, Mengxi Tian, Rowena Martinez, Rishi Savur, Alyssa Peery-McNamara, Don-Hong Wang, Ori Maller, Dharini Iyer, Ashita Magal, Sravani Mangalampalli, Christina J Huynh, Carmina C Blanco, Jack T Lin, Brian S Garrison, Philip Lee, Timothy K Lu, Gary Lee., SENTI-101, an allogeneic cell product, induces potent and durable anti-tumor immunity in preclinical models of peritoneal carcinomatosis. 34th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019): Part 1., 2019.
  58. RoosterBio. Cryopreserved hMSCs maintain comparable in vitro functional activity compared to fresh hMSCs. RoosterBio Blog 2015; Available from: https://www.roosterbio.com/mscs-characterization/cryopreserved-hmscs-maintain-comparable-in-vitro-functional-activity-compared-to-fresh-hmscs/.
  59. Content and Review of Chemistry, Manufacturing, and Control (CMC) Information for Human Somatic Cell Therapy Investigational New Drug Applications (INDs). U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research, 2008.
  60. Yuan, X., et al., Aggregation of Culture Expanded Human Mesenchymal Stem Cells in Microcarrier-based Bioreactor. Biochem Eng J, 2018. 131: p. 39-46. 10.1016/j.bej.2017.12.011
  61. Galipeau, J., et al., International Society for Cellular Therapy perspective on immune functional assays for mesenchymal stromal cells as potency release criterion for advanced phase clinical trials. Cytotherapy, 2016. 18(2): p. 151-9. 10.1016/j.jcyt.2015.11.008
  62. Phinney, D. G., et al., Manufacturing mesenchymal stromal cells for clinical applications: A survey of Good Manufacturing Practices at U.S. academic centers. Cytotherapy, 2019. 21(7): p. 782-792. 10.1016/j.jcyt.2019.04.003
  63. Robb, K. P., et al., Mesenchymal stromal cell therapy: progress in manufacturing and assessments of potency. Cytotherapy, 2019. 21(3): p. 289-306. 10.1016/j.jcyt.2018.10.014
  64. Liu, A., et al., Therapeutic potential of mesenchymal stem/stromal cell-derived secretome and vesicles for lung injury and disease. Expert Opin Biol Ther, 2020. 20(2): p. 125-140. 10.1080/14712598.2020.1689954
  65. Worthington, E. N. and Hagood, J. S., Therapeutic Use of Extracellular Vesicles for Acute and Chronic Lung Disease. Int J Mol Sci, 2020. 21(7). 10.3390/ijms21072318
  66. Abraham, A. and Krasnodembskaya, A., Mesenchymal stem cell-derived extracellular vesicles for the treatment of acute respiratory distress syndrome. Stem Cells Transl Med, 2020. 9(1): p. 28-38. 10.1002/sctm.19-0205
  67. Charoenviriyakul, C., Takahashi, Y., Nishikawa, M., & Takakura, Y. (2018). Preservation of exosomes at room temperature using lyophilization. Int J Pharm, 553(1-2), 1-7. doi:10.1016/j.ijpharm.2018.10.032
  68. Börger, V., et al., ISEV and ISCT statement on EVs from MSCs and other cells: considerations for potential therapeutic agents to suppress COVID-19. Cytotherapy, 2020. doi:10.1016/j.jcyt.2020.05.002
  69. Sengupta, V., Sengupta, S., Lazo, A., Jr., Woods, P., Nolan, A., & Bremer, N. (2020). Exosomes Derived from Bone Marrow Mesenchymal Stem Cells as Treatment for Severe COVID-19. Stem Cells Dev. doi:10.1089/scd.2020.0080
  70. Zhu, Y. G., et al., Human mesenchymal stem cell microvesicles for treatment of Escherichia coli endotoxin-induced acute lung injury in mice. Stem Cells, 2014. 32(1): p. 116-25. 10.1002/stem.1504
  71. Adlerz, K. (2020). Accelerating COVID-19 Treatments with Patient Safety As First Priority. RoosterBio Blog. Retrieved from https://www.roosterbio.com/covid-19/accelerating-covid-19-treatments-with-patient-safety-as-first-priority
  72. Lembong, J. (2020). Productivity Metric Considerations in MSC & MSC-EV Manufacturing in Response to COVID-19. RoosterBio Blog. Retrieved from https://www.roosterbio.com/evs-exosomes/productivity-metric-considerations-in-msc-msc-ev-manufacturing-in-response-to-covid-19/
  73. Lembong, Josephine, et al., A scalable xeno-free microcarrier suspension bioreactor system for regenerative medicine biomanufacturing of hMSCs. 2019.
  74. Lawson, Tristan, et al., Process development for expansion of human mesenchymal stromal cells in a 50L single-use stirred tank bioreactor. Biochemical Engineering Journal, 2017. 120: p. 49-62. https://doi.org/10.1016/j.bej.2016.11.020
  75. McGlothlen, Michael, et al., Use of microcarriers in Mobius® CellReady bioreactors to support growth of adherent cells. BMC Proceedings, 2013. 7: p. P95. 10.1186/1753-6561-7-S6-P95
  76. Ferguson, Neil M, et al., Impact of non-pharmaceutical interventions (NPIs) to reduce COVID-19 mortality and healthcare demand. London: Imperial College COVID-19 Response Team, March, 2020. 16.
  77. University, Johns Hopkins. Coronavirus Resource Center. 2020; Available from: https://coronavirus.jhu.edu/map.html.
  78. Organization, World Health. Ebola virus disease. 2020; Available from: https://www.who.int/health-topics/ebola/#tab=tab_1.

We're fueling the rapid commercialization of scalable regenerative cures. If you're interested in having a conversation about how RoosterBio can accelerate your product & process development and shorten your time to the clinic, contact us.

Write a Comment

Your email address will not be published. Required fields are marked *